Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Staels, Bart; Rubenstrunk, A.; Noël, Benoît; Rigou, Géraldine; Delataille, Philippe; J. Millatt, Lesley; Baron, Morgane; Lucas, Anthony; Tailleux, Anne; W. Hum, Dean; Ratziu, Vlad; Cariou, Bertrand; Hanf, Rémy

doi:10.1002/hep.26461

Public

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Published in Hepatology • May 22, 2013

Authors:

Bart Staels

A. Rubenstrunk

Benoît Noël

Abstract

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no pharmacological treatment is approved for NAFLD/NASH. Here, we report on preclinical and clinical data wit...

Subject

Nonalcoholic fatty liver disease

Internal medicine

Endocrinology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!